DEST.L Stock - Destiny Pharma plc
Unlock GoAI Insights for DEST.L
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $831,552 | $154,499 | $135,028 | $12,450 | $305,906 |
| Gross Profit | $825,356 | $142,171 | $122,510 | $-4,431 | $287,466 |
| Gross Margin | 99.3% | 92.0% | 90.7% | -35.6% | 94.0% |
| Operating Income | $-6,569,960 | $-7,886,170 | $-6,433,740 | $-6,553,470 | $-5,844,870 |
| Net Income | $-5,657,036 | $-6,503,569 | $-5,339,480 | $-5,411,077 | $-4,708,024 |
| Net Margin | -680.3% | -4209.5% | -3954.4% | -43462.5% | -1539.0% |
| EPS | $-0.06 | $-0.09 | $-0.09 | $-0.12 | $-0.11 |
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase III clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in Phase I clinical trial for the treatment of skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Biofilm that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF drugs for the treatment of respiratory, oral mucosa, and ocular infection diseases. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; the University of Southampton; Aston University; the University of Sheffield; and Cardiff University and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.
Visit WebsiteEarnings History & Surprises
DEST.LEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2025 | Apr 23, 2025 | — | — | — | — |
Q3 2024 | Sep 18, 2024 | — | — | — | — |
Q2 2024 | Apr 25, 2024 | — | $-0.03 | — | — |
Q3 2023 | Sep 20, 2023 | — | $-0.03 | — | — |
Q2 2023 | Apr 13, 2023 | — | $-0.05 | — | — |
Q3 2022 | Sep 8, 2022 | — | $-0.05 | — | — |
Q2 2022 | Apr 12, 2022 | — | $-0.05 | — | — |
Q3 2021 | Sep 9, 2021 | — | $-0.04 | — | — |
Q2 2021 | Apr 14, 2021 | — | $-0.06 | — | — |
Q3 2020 | Sep 17, 2020 | — | $-0.06 | — | — |
Q2 2020 | Apr 29, 2020 | — | $-0.06 | — | — |
Q3 2019 | Sep 23, 2019 | — | $-0.05 | — | — |
Q2 2019 | Apr 9, 2019 | — | $-0.07 | — | — |
Q3 2018 | Sep 26, 2018 | — | $-0.05 | — | — |
Q2 2018 | Apr 12, 2018 | — | $-0.05 | — | — |
Q3 2017 | Sep 5, 2017 | — | $-0.03 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-0.03 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.01 | — | — |
Q4 2015 | Dec 31, 2015 | — | $-0.01 | — | — |
Q2 2015 | Jun 30, 2015 | — | $-0.01 | — | — |
Latest News
Frequently Asked Questions about DEST.L
What is DEST.L's current stock price?
What is the analyst price target for DEST.L?
What sector is Destiny Pharma plc in?
What is DEST.L's market cap?
Does DEST.L pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to DEST.L for comparison